Key result
NOACs offer viable alternatives to warfarin for AFib stroke prevention but require individualized patient selection.
Why the study?
Many patients with atrial fibrillation are managed with anticoagulation, and novel oral anticoagulants provide alternative options to warfarin requiring individualized decision making.
Novel oral anticoagulants offer alternatives to warfarin for patients with atrial fibrillation, requiring individualized decision-making based on safety, efficacy, and tolerability.
Answers are grounded in this paper and cite their sources.
Supports individualized NOAC selection in AF; leaves open head-to-head real-world comparisons on long-term outcomes.
Because atrial fibrillation (AF) is a major risk for thrombotic disease, many patients with AF are managed with anticoagulation for primary or secondary prevention of these events. The emergence of novel oral anticoagulants offers patients and providers options to consider beyond warfarin. Decision making should address safety, tolerability, efficacy, price, and simplicity of use; and decisions should be individualized for each patient.
No takes yet. Share an insight, caveat, or question.
Webster et al. (2018) conducted a review in Atrial fibrillation. Novel oral anticoagulants vs. Warfarin was evaluated. Novel oral anticoagulants offer alternatives to warfarin for stroke prevention in atrial fibrillation, requiring individualized decisions based on safety, efficacy, and cost.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: